 Home > Active Ingredient News >

Antitumor Therapy

NAT COMMUN: Fasting plus Vc, anti-cancer combination

 Time of Update: 2020-05-29

protein 3 chemotherapy cervical cancer cancer cell growth prostate cancer biomarkers skin cancer images

The hunger-simulated diet can slow tumor progression and make multiple tumors sensitive to chemotherapy, but so far we do not know much about the therapeutic potential of its combination with noncy
Blood: Targetbone myrita can save the impaired hematopoietic stem cell function of beta-thalassemia

 Time of Update: 2020-05-29

stem cell capsule bone diseases bone marrow diseases list body characteristics microtubule associated protein

Hematopoietic stem cells (HSCs) are regulated by signals from bone marrow (BM) niches, which regulate blood cell production in stable states and in blood diseases To understand the role of HSC-wall
20-year-old young man's trachea narrows into "a seam" Shanghai expert successfully opens the "main road" of life

 Time of Update: 2020-05-29

lungs function respiratory system dawn simply clean 2 15 16 mm old time beer white 1

before the operation, the trachea had become "a fine seam" Chest hospital for the Shanghai, May 15 (Chen Jing Dengtian) reporter was informed on the 15th, a tumor pressure, the trachea is extrem
How is METex14-related NSCLC treated? FDA takes positive view of MET inhibitor Tabrecta

 Time of Update: 2020-05-29

phase 4 trial cancer cell proliferation fda approval search cancer cell lines human cell lines

Novartis Pharmaceuticals said recently that the FDA has accelerated approval of tabrecta (capmatinib) applications to treat adult patients with metastatic non-small cell lung cancer (NSCLC), whose
NAT MED: China Announces Results of First CRISPR Human Trial

 Time of Update: 2020-05-29

nylon 6 12 10 3 ground crispr agriculture fe co 5 cell

Existing studies have shown that CRISPR-Cas9 editing immune checkpoint genes can improve the efficacy of T-cell therapy, but we need to understand first about its safety and feasibility here, chi
Phase III Clinical: Sanofi's CD38 monosaclisa significantly reduces the risk of death in patients with multiple myeloma recurrence

 Time of Update: 2020-05-29

multiple sclerosis progression ritalin 10 mg mg 4 meloxicam drug test librium 10 mg

Sanofi's anti-CD38 monoclonal antibody, Sarclisa (isatuximab), reached the end of the trial early in a Phase III clinical trial, significantly reducing the risk of disease progression or death in p
Nat Commun: Study confirms that triple therapy for fasting and vitamin C-plus chemotherapy is effective for hard-to-treat cancers

 Time of Update: 2020-05-29

cyanide side effects calculate cycle time natural vitamin supplement biotin vitamin b7 high iron supplement

Introduction: According to different preclinical and clinical trials, the pharmacological dose of vitamin C (ascorbic acid) has been proposed as a potential anti-cancer drug Recent studies have sho
Phase IIb clinical trial for the first anti-tumor candidate plant drug "YIV-906" in combination with Sorafeni for the treatment of hepatocellular carcinoma has been launched

 Time of Update: 2020-05-29

catalyst science definition clonazepam drug test vetoryl side effects food manufacturing companies natural body wash chemicals

Yiviva Inc., a biopharmaceutical innovation company, officially launched the First-Line Treatment IIb Phase Of YIV-906 Co-Solafini for hepatitis B-Associated Hepatocellular Carcinoma (HCC) in early
ASCO 2020: PD-1 mono-anti-Opdivo, CTLA-4 mono-Yervoy combination chemotherapy first-line treatment of non-small cell lung cancer, reducing risk of death by 31%

 Time of Update: 2020-05-29

breast cancer histology single cell cancer lewis lung carcinoma renal metastatic liver cancer

Bristol Myers Squibb announced the detailed results of its CheckMate-9LA trial, which showed that the use of PD-1 mono-anti-Opdivo (nivolumab) and CTLA-1 mono-resistant Yervoy (ipilimumab) chemothe
Female, found double lower limb edema in February, right chest pain January, please diagnose!

 Time of Update: 2020-05-29

1 4 benzoquinone low voice gas what reactive depression changes state water deep sea water

Diagnosing peripheral lung cancer?
Cell Death Dis: LncRNA KCNQ1OT1 Promotes Osteosarcoma Progress by Enhancing Aerobic Sugar Enzymes

 Time of Update: 2020-05-29

born cancer cells long chain triglycerides a cabinets cancer cell differentiation enzyme process

Ostoma (OS) is one of the most invasive and common primary malignant bone tumors, most common in children and adolescents With the progress of various treatments, such as surgery, chemotherapy and
PLoS Biol: Yap inhibits T-cell function and leaching in tumor microenvironment

 Time of Update: 2020-05-29

gene expression bacteria cell ra factor positive factor 4 cd4 cells function

A major challenge in cancer immunotherapy is to maintain the activation and recruitment of T cells in immunosuppressive solid tumors Here, we report that the level of the Hippo path effect factor Y
Rubraca approved in U.S. as first PARP inhibitor approved for prostate cancer

 Time of Update: 2020-05-29

prostate medication flomax fda sro list conducting 3 4 lee tiffany cancer exosomes cancer

Clovis Oncology announced that the U.S Food and Drug Administration (FDA) has approved its oral PARP inhibitor Rubraca (rucaparib) tablets for adult patients with BRCA mutations in metastatic neuro
Nat Neuro: New immunotherapy combination may be effective in treating pediatric brain cancer

 Time of Update: 2020-05-29

short term incentive hydrocortisone 1 percent fast narcan work testosterone half life antibiotics immune system

Introduction: Oncologists know that "chemotherapy and radiotherapy" is one of the preferred anti-cancer therapies Because the combination of chemotherapy can kill cancer cells more effectively Howe
Professor Xu Jianmin Explains Treatment for Hepatometymety Patients With Non-Recital Colorectal Cancer (BECOME Study)

 Time of Update: 2020-05-29

vc group kelnor 1 50 viagra original use hcs group prolene 3 0

In 2013, Professor Xu Jianmin's team published the results of treatment for RAS wild-type CRC liver metastasis patients with citoxil monoantigen combined with mFOLFOX6 in Journal of Clinical Oncolo
Nature Sub-journal: Triple therapy for fasting and vitamin C-plus chemotherapy is effective for hard-to-treat cancers

 Time of Update: 2020-05-29

1 2 dichloropropane what vitamin skin body store protein darifenacin side effects cancer cell cycle

A study published May 11 in Nature Communications shows that the combination of fasting and vitamin C has an effect on the of untreatable cancers scientists at the University of Southern Califo
NAT MED: Antioxidant Key Protein Spromotes Relapse of Dormant Tumor Cells?

 Time of Update: 2020-05-29

cancer cell differentiation high ferritin treatment soy breast cancer ureter cancer treatment balance

Dormant tumor cells survive and relapse after treatment are the leading causes of death in cancer patients Previous studies have shown that the metabolic properties of these cells may differ from t
Ten Questions and Ten Answers to the HPV Vaccine FAQ

 Time of Update: 2020-05-29

what situ hybridization what difference types frankincense what capital market what matrixyl 3000 what titanium

The HPV vaccine, also known as the cervical cancer vaccine, is a virus-like particle synthesized using gene recombination techniques based on various types of HPVL1 shell protein Belongs to the second category of vaccine (at self-funded, about 2000-3000 yuan), voluntary vaccination Vaccination against HPV reduces hVP prevalence in the population, reduces the risk of infection for yourself and your partner, and reduces the risk of cervical cancer due to HPV infection what are the current HPV vaccines ?
Professor Chen Wenyan Interview: T-DM1 Brings Treatment Innovation stort for Breast Cancer, Patient Assistance Project Helps Early Treatment of Breast Cancer

 Time of Update: 2020-05-29

mobile phase paper chromatography research pest control benefits eating fish docusate side effects hs treatment

T-DM1 is officially available in China, which is great news for HER2-positive breast cancer patients, especially HER2-positive patients who have not achieved full pathological remission after new c
CheckMate-227 Three-year follow-up data confirm that Odivo (Navuriu monoantigen) combined with Ipitaph monoantigen for first-line metastatic non-small cell lung cancer patients with long-term and long-term survival benefits

 Time of Update: 2020-05-29

earth 2 society iron lung disease short term memory cancer nanotechnology immigrants come year

On May 13, 2020, Shiguibao of Boxei announced the results of a three-year follow-up to Part 1 of Phase III Clinical Study CheckMate 227 The results showed that Odivo's combination of Epiwood monoan

Go to Page

Antitumor Therapy

NAT COMMUN: Fasting plus Vc, anti-cancer combination

Blood: Targetbone myrita can save the impaired hematopoietic stem cell function of beta-thalassemia

20-year-old young man's trachea narrows into "a seam" Shanghai expert successfully opens the "main road" of life

How is METex14-related NSCLC treated? FDA takes positive view of MET inhibitor Tabrecta

NAT MED: China Announces Results of First CRISPR Human Trial

Phase III Clinical: Sanofi's CD38 monosaclisa significantly reduces the risk of death in patients with multiple myeloma recurrence

Nat Commun: Study confirms that triple therapy for fasting and vitamin C-plus chemotherapy is effective for hard-to-treat cancers

Phase IIb clinical trial for the first anti-tumor candidate plant drug "YIV-906" in combination with Sorafeni for the treatment of hepatocellular carcinoma has been launched

ASCO 2020: PD-1 mono-anti-Opdivo, CTLA-4 mono-Yervoy combination chemotherapy first-line treatment of non-small cell lung cancer, reducing risk of death by 31%

Female, found double lower limb edema in February, right chest pain January, please diagnose!

Cell Death Dis: LncRNA KCNQ1OT1 Promotes Osteosarcoma Progress by Enhancing Aerobic Sugar Enzymes

PLoS Biol: Yap inhibits T-cell function and leaching in tumor microenvironment

Rubraca approved in U.S. as first PARP inhibitor approved for prostate cancer

Nat Neuro: New immunotherapy combination may be effective in treating pediatric brain cancer

Professor Xu Jianmin Explains Treatment for Hepatometymety Patients With Non-Recital Colorectal Cancer (BECOME Study)

Nature Sub-journal: Triple therapy for fasting and vitamin C-plus chemotherapy is effective for hard-to-treat cancers

NAT MED: Antioxidant Key Protein Spromotes Relapse of Dormant Tumor Cells?

Ten Questions and Ten Answers to the HPV Vaccine FAQ

Professor Chen Wenyan Interview: T-DM1 Brings Treatment Innovation stort for Breast Cancer, Patient Assistance Project Helps Early Treatment of Breast Cancer

CheckMate-227 Three-year follow-up data confirm that Odivo (Navuriu monoantigen) combined with Ipitaph monoantigen for first-line metastatic non-small cell lung cancer patients with long-term and long-term survival benefits